LINC01794: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC01794

NCBI ID: G101929700

LINC01794

Other Name(s): Long intergenic non-protein coding RNA 1794, transcript variant X4 | long intergenic non-protein coding RNA 1794 | LINC01794 variant X4

LINC01794: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC01794 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various studies. It is a non-coding RNA molecule that is involved in various cellular processes in animals, including gene regulation, RNA processing, and cell signaling. In recent years, researchers have become interested in investigating the potential role of lncRNA as a drug target or biomarker. This article will provide an overview of LINC01794, its potential drug target potential, and its role as a biomarker in various diseases.

Potential Drug Target

The potential drug target for LINC01794 is its role in cell signaling pathways. LncRNA have been shown to play a critical role in intracellular signaling cascades, which are the pathways by which cells communicate with each other and with their surroundings. LINC01794 is a key lncRNA in the HIF-1?± pathway, which is involved in the regulation of oxygen homeostasis, and has been shown to play a critical role in this pathway.

The HIF-1?± pathway is a complex signaling pathway that is involved in the regulation of various cellular processes, including cell growth, apoptosis, and angiogenesis. The HIF-1?± pathway is activated in response to changes in oxygen levels, and it is responsible for regulating the production of oxygen and the sensitivity of cells to oxygen. LINC01794 is a key player in this pathway, as it has been shown to regulate the activity of the HIF-1?± transcription factor.

Research has shown that LINC01794 is highly expressed in various tissues, including brain, heart, and pancreas, and that it is involved in the regulation of cellular processes such as cell growth, apoptosis, and angiogenesis. Additionally, studies have shown that LINC01794 is involved in the regulation of cellular signaling pathways, including the HIF-1?± pathway.

Potential Biomarker

LINC01794 has also been identified as a potential biomarker for various diseases, including cancer. The HIF-1?± pathway is a critical signaling pathway that is involved in the regulation of various cellular processes, including cell growth, apoptosis, and angiogenesis. As such, LINC01794 has been shown to be involved in the regulation of these processes, which makes it a potential biomarker for various diseases.

Studies have shown that LINC01794 is highly expressed in various tissues and that it is involved in the regulation of cellular processes, including cell growth, apoptosis, and angiogenesis. Additionally, research has shown that LINC01794 is involved in the regulation of cellular signaling pathways, including the HIF-1?± pathway. These findings suggest that LINC01794 may be a potential biomarker for various diseases.

Conclusion

In conclusion, LINC01794 is a long intergenic non-protein-coding RNA that is involved in various cellular processes, including cell signaling pathways. Its potential drug target is its role in the HIF-1?± pathway, which is involved in the regulation of oxygen homeostasis. Additionally, LINC01794 has been shown to be involved in the regulation of various cellular processes, including cell growth, apoptosis, and angiogenesis, making it a potential biomarker for various diseases. Further research is needed to fully understand the role of LINC01794 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1794

The "LINC01794 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01794 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets